Table 1.
Patient demographics
| In vitro analysis | In vivo analysis | ||
|---|---|---|---|
| Biopsy-only group (n = 16) | Saline group (n = 8) | GTN group (n = 13) | |
| Age (years) | 64.5 ± 3.8 | 62 ± 4.0 | 66 ± 3.3 |
| Male gender, n (%) | 13 (81) | 7 (88) | 12 (92) |
| Mean weight (kg) | 78.3 ± 3.8 | 74.6 ± 2.5 | 82.3 ± 3.3 |
| Body mass index (kg·m–2) | 27.8 ± 1.5 | 25.4 ± 0.5 | 27.1 ± 0.9 |
| Ejection fraction (%) | 26.4 ± 2.3 | 25.1 ± 2.5 | 27 ± 2.1 |
| NYHA class | |||
| I | 2 | 1 | 1 |
| II | 6 | 4 | 10 |
| III | 8 | 3 | 2 |
| Heart rate (beats·min-1) | 72 ± 2.8 | 62 ± 4.4 | 62 ± 2.0 |
| MABP (mmHg) | 95 ± 4.1 | 89 ± 2.9 | 88 ± 2.2 |
| Aetiology, n (%) | |||
| Dilated cardiomyopathy | 8 (50) | 5 (62) | 6 (46) |
| Ischaemic cardiomyopathy | 6 (38) | 3 (38) | 6 (46) |
| Other | 2 (13) | 0 | 1 (8) |
| Medication, n (%) | |||
| ACEI/AT2 receptor antagonists | 15 (94) | 8 (1 00) | 12 (92) |
| β-Blockers | 10 (63) | 5 (62) | 10 (77) |
| Spironolactone/eplerenone | 10 (63) | 3 (38) | 3 (23) |
| Loop diuretic | 12 (75) | 4 (50) | 8 (62) |
| Aspirin | 12 (75) | 4 (50) | 10 (77) |
Data expressed as mean ± SEM.
ACEI, ACE inhibitors; MABP, mean arterial BP; NYHA, New York Heart Association classification.